Alterity Therapeutics (ASX:ATH) doses first European patient in phase two MSA trial
Alterity Therapeutics (ATH) has dosed its first patient in Italy as part…
Alterity Therapeutics Limited (ASX:ATH)
About Alterity Therapeutics Limited
Key Information
ATH In the News
ASX Announcements
| Date | Announcement | File | Views |
|---|---|---|---|
| 09.20am 04/12/2023 | Price Sensitive PS Positive Efficacy Data for ATH434 in a Primate Model of PD | 202.46KB | 746 |
| 01/12/2023 | Change in substantial holding | 1.52MB | 159 |
| 30/11/2023 | Notice of Extraordinary General Meeting/Proxy Form | 578.65KB | 228 |
| 30/11/2023 | Notification of cessation of securities - ATH | 21.6KB | 146 |
| 29/11/2023 | Results of Annual General Meeting | 304.67KB | 580 |
| 29/11/2023 | Notice Under Section 708A | 85.08KB | 133 |
| 29/11/2023 | Application for quotation of securities - ATH | 24.7KB | 396 |
| 29/11/2023 | Alterity completes Placement Tranche One raising $1.3M | 201.6KB | 156 |